Improvement in Inner Retinal Function in Glaucoma in Response to Nicotinamide (Vitamin B_3) Supplementation: A Crossover Randomized Clinical Trial

Authors: Flora Hui, BOptom PhD[1,†], Jessica Tang, MBBS(Hons) BMedSci[1,2], Pete A Williams, BSc(Hons) PhD[3], Myra B McGuinness, MBiostat PhD[1], Xavier Hadoux, MEng PhD[1], Robert J Casson, PhD FRANZCO[4], Michael Coote, MBBS FRANZCO[1,2], Ian A Trounce PhD[1,2], Keith R. Martin, DM FRCOphth[1,2,5], Peter van Wijngaarden, PhD FRANZCO[1,2], Jonathan G Crowston, PhD FRANZCO[1,2,6,7]

Financial support: Ophthalmic Research Institute of Australia (FH); Jack Brockhoff Foundation, Marian and E.H. Flack Trust – JBF Grant number 4354 – 2017 (FH); Jean Miller Foundation (JGC); Connie and Craig Kimberley Fund (IAT, JGC). Board of Research Faculty Funded Career position (Karolinska Institutet) (PAW). The Centre for Eye Research Australia receives operational infrastructure support from the Victorian Government. The funding organisations had no role in the design or conduct of this research.

Running head: Nicotinamide improves retinal function in glaucoma

Word count: 3500

Abbreviations and Acronyms: ATP – adenosine triphosphate, CI – confidence interval, COR – coefficient of repeatability, ERG – electroretinogram, IOL – intraocular lens, IOP – intraocular pressure, IQR – interquartile range, MD – mean deviation, MLS – mean light

[1] Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia
[2] Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Australia
[3] Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden
[4] Ophthalmic Research Laboratories, Discipline of Ophthalmology and Visual Sciences, University of Adelaide, Adelaide, Australia
[5] Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
[6] Centre for Vision Research, Duke-NUS Medical School, Singapore
[7] Singapore Eye Research Institute, Singapore National Eye Centre, Singapore
[†] Corresponding author

sensitivity, NAD^+ – nicotinamide adenine dinucleotide, NAM – nicotinamide, PL – placebo, POAG – primary open-angle glaucoma, PhNR – photopic negative response, PSD – pattern standard deviation, Q1 – lower quartile, Q3 – upper quartile, RGC – retinal ganglion cell, RNFL – retinal nerve fibre layer, VF – visual field, Vmax – saturating amplitude

Corresponding author:

Dr Flora Hui

Centre for Eye Research Australia

Level 7, Peter Howson Wing, 32 Gisborne Street

East Melbourne, VIC 3002, Australia

f.hui@unimelb.edu.au

Acknowledgements: Professor David Crabb for his advice on visual field analyses.

Conflict of interest: No conflicting relationship exists for any author.

Data sharing statement: Clinical data was collected at the Centre for Eye Research Australia in collaboration with the Royal Victorian Eye and Ear Hospital and Melbourne Eye Specialists. These data are not publicly available. Source data of graphs may be available as source files if requested. A description of the code used to analyze the electroretinogram data is described in the Methods section, and we have also published this previously (Tang et al, 2018).

Abstract

Importance: Retinal ganglion cells endure significant metabolic stress with ageing and glaucoma-related stressors. Injured cells require increased energy for repair but maintain capacity to recover function despite periods of functional loss. Nicotinamide, a precursor of redox co-factor and metabolite, NAD^+, is low in serum of patients with primary open-angle glaucoma and its supplementation provides robust protection of retinal ganglion cells by targeting mitochondrial health in glaucoma models. However, the potential of nicotinamide to improve retinal ganglion cell function in humans with glaucoma is yet unknown.

Objective: To determine whether nicotinamide supplementation taken in conjunction with conventional IOP-lowering therapy leads to early improvement in retinal ganglion cell function in people with glaucoma.

Design: Crossover, double-masked, randomized clinical trial conducted between October 2017 to January 2019.

Setting: Study participants recruited from two tertiary care centers in Melbourne, Australia.

Participants: Adults diagnosed and treated for primary glaucoma. Ninety-four participants assessed for study eligibility.

Intervention: Participants randomized to first receive oral placebo or nicotinamide and reviewed six-weekly. Accelerated dosing method utilized; participants commenced 6-week course of 1.5 grams/day followed by 6 weeks of 3.0 grams/day. After 12 weeks, participants crossed over to other intervention for 12 weeks without washout. At each visit, visual function measured using full-field flash electroretinography and white-on-white perimetry.

Main outcome measures: Primary endpoint was change in inner retinal function determined a-priori as change in photopic negative response (PhNR) parameters: saturated PhNR amplitude (Vmax), ratio of PhNR/b-wave amplitude (Vmax ratio).

Results: Fifty-seven participants (65.5±10.0 years, 39% female) enrolled. PhNR Vmax improved beyond 95% coefficient of repeatability (COR) in 23% of participants following 12 weeks of nicotinamide versus 9% on placebo. Conversely, PhNR Vmax deteriorated in 9% on placebo and 7% on nicotinamide. Overall, Vmax improved by 14.8% [95% CI: 2.8%, 26.9%], (p=0.02) on nicotinamide and 5.2% [-4.2%, 14.6%], (p=0.27) on placebo. Vmax ratio improved on average by 12.6% [5.0%, 20.2%], (p=0.002) following nicotinamide and 3.6% [-3.4%, 10.5%], (p=0.30) on placebo. A concomitant trend for improved visual field mean deviation was observed with 27% improving ≥1dB on nicotinamide and fewer deteriorating ≥1dB (4%) compared to placebo (p=0.02). Moderate correlation was observed between PhNR and visual field change with treatment. Participants demonstrated excellent treatment adherence rates (>94%) and nicotinamide was well tolerated with minimal side effects.

Conclusions and Relevance: Nicotinamide supplementation can improve inner retinal function in patients receiving concurrent IOP-lowering glaucoma therapy. Further studies are underway to elucidate the effects of long-term nicotinamide supplementation on glaucoma progression.

Trial Registration: ANZCTR trial ID: ACTRN12617000809336
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373001

Main Text

Glaucoma remains the leading cause of irreversible blindness worldwide.[1] The disease has a complex aetiology and range of risk factors but is characterised by gradual dysfunction and loss of retinal ganglion cells (RGCs) and their axons which make up the optic nerve.[2,3] This slow, progressive loss of visual function hinders the translation of potential neuroprotective therapeutics from bench-to-bedside due to the extended time needed to determine treatment-induced changes in glaucoma progression rates. Age,[1,4] genetics,[5] and elevated intraocular pressure (IOP)[6] are all major risk factors for glaucoma yet clinically available treatment strategies target only IOP-lowering, and do not directly target the neurodegenerative events at the level of the retina and optic nerve. As many patients are refractory to IOP lowering or progress to blindness despite low IOP, neuroprotective strategies that directly target RGC health and decrease vulnerability to glaucoma-related cellular stressors are urgently needed. Accumulating evidence points to the potential for visual recovery in clinical glaucoma in response to IOP-lowering.[7-9] Recovery of visual function can occur soon after restoration of IOP and, as such, objective measures of visual function have potential as surrogate biomarkers of improved RGC health.

The photopic negative (PhNR) and positive scotopic threshold responses are parameters of the electroretinogram (ERG) that are largely generated by RGCs in the inner retina.[26-30] RGC function has been shown to recover after acute and chronic IOP insults even after prolonged periods of functional loss.[31-35] Capacity for recovery is reduced with advancing age[36] and can be modified by interventions such as exercise and diet restriction.[37,38] Using ERG protocols similar to those validated in rodent studies, we have demonstrated improvements in RGC function in humans, as early as 3-months following IOP-lowering in glaucoma.[7] Recent work has significantly improved repeatability of the PhNR measurement, enabling detection of subtle changes in inner retinal function.[39,40]

Several lines of evidence implicate oxidative stress and mitochondrial dysfunction in ageing[10] and RGC loss in glaucoma.[11,12] Nicotinamide adenine dinucleotide (NAD^+) is an essential cofactor for ATP generation in mitochondria, and for NAD-consuming enzymes including sirtuins (eFigure 1 in Supplement), with important roles in ageing, cell senescence, and stress resistance.[13] NAD^+ is a potent mediator of axon neuroprotection and recently, the therapeutic potential of modulating NAD^+ metabolism has gained widespread attention in its role in ageing and neurodegenerative disease.[14-21] A number of studies are currently investigating the effect of NAD^+ repletion in a range of neurodegenerative disorders including Alzheimer's disease (NCT00580931, NCT03061474) and peripheral small fibre neuropathy (NCT03912220). Recent work has indicated that patients with primary open-angle glaucoma (POAG) have reduced serum levels of nicotinamide (NAM, the amide of vitamin B_3 and precursor for NAD^+), indicating that systemic NAD^+ levels may be associated with susceptibility to glaucoma.[22] In support of this hypothesis, Williams et al[23] demonstrated that increasing retinal NAD^+ levels with dietary NAM or overexpression of a NAD-producing enzyme (*Nmnat1*) provided robust long-term neuroprotection of RGCs, reversed age-related transcriptomic changes, and preserved RGC function in an inherited mouse model of glaucoma (DBA/2J). These findings support the hypothesis that NAM supplementation has therapeutic potential. In addition, NAM has been safely used in a number of clinical studies with minimal adverse effects[24,25] and, as such, NAM supplementation may be readily translated into clinical care and complement current therapies.

We therefore sought to determine whether functional improvements observed with NAM supplementation in mice could be recapitulated in humans with glaucoma in an interventional study using the ERG PhNR and visual fields (VF) as main outcome measures. This study sought to determine whether NAM, a potential neuroprotectant that targets bioenergetic insufficiency in glaucoma, could lead to a detectable improvement in inner retinal function.

Methods

Study Design, Participants

This study was a prospective, double-masked, randomized, crossover clinical trial conducted in Melbourne, Australia between October 2017 and January 2019. The trial protocol is provided in Supplement 1 and study schedule is presented in eFigure 2 in Supplement 2. All procedures were approved by the Human Research Ethics Committee at the Royal Victorian Eye and Ear Hospital (17/1339H). Written informed consent was obtained from all participants prior to all procedures. Participants were recruited from public outpatient and private ophthalmology clinics (Royal Victorian Eye and Ear Hospital, Melbourne Eye Specialists). All testing was performed at the Centre for Eye Research Australia. Inclusion and exclusion criteria are presented in the eMethods in Supplement 2.

As this study involved high-dose NAM, an accelerated dosing protocol was used to facilitate tolerability. Participants were randomized 1:1 with randomly selected block sizes of 4, 6 and 8 using a computer-generated list to the intervention in either the first or second study period. The intervention consisted of a 6-week course of NAM (Insolar®, 0.5 g NAM tablet, Blackmores, NSW, Australia) of 1.5 g/day followed by 6 weeks of 3.0 g/day, (1.5 g twice a day). Placebo (PL) tablets were manufactured to match the appearance and texture of the active treatment (Pharmaceutical Packaging Professionals, Melbourne, Australia). Placebo and active treatment bottles were identical and coded with unique numerical identifiers. Participants randomized to receive placebo also doubled the number of tablets after 6 weeks to ensure they remained masked. Treatment was dispensed by the study coordinator at the conclusion of Visit 1 following capture of baseline measurements. Participants, treating physicians, certified assessors and biostatistician were masked to treatment allocation. The

NAM dosage of 3.0 g/day was based on that used in preclinical studies,[23] other published[24] and ongoing human trials of NAM treatment (NCT00580931, NCT03061474).

After 12 weeks, participants crossed over without washout, such that those previously on placebo treatment commenced NAM and vice versa. A washout was deemed unnecessary as any effect from NAM was assumed to be undetectable by the time of the next review visit. Treatment was taken in conjunction with any glaucoma therapies participants were already using. To monitor treatment adherence, participants were asked to bring remaining tablets to each study visit and tablets were manually counted by the study coordinator. A minimum adherence rate of 70% was acceptable, equating to no more than two missed doses a week.

Clinical Testing

All participants were seen at baseline (Visit 1), and reviewed 6-weekly (±2 weeks). At each visit, participants underwent a standard clinical examination, including measurement of visual acuity (EDTRS letters in logMAR units), IOP (Icare® PRO, Icare Finland Oy, Finland), blood pressure (HEM-7322, Omron Healthcare, Japan) and slit lamp examination. Standard automated perimetry was performed on the study eye (SITA-Standard 24-2, HFA II-750i, Carl Zeiss Meditec AG, Germany) and pupils were dilated (to ≥6 mm) using 0.5% tropicamide and 2.5% phenylephrine (Bausch and Lomb, NSW, Australia). Participants were light-adapted for at least 10 minutes before photopic ERG recording. ERGs were recorded with custom-made DTL-like electrodes using silver impregnated fibre (22/1 dtex, Shieldex trading, NY, USA) and a handheld device (RETeval™, LKC Technologies, MD, USA). Reference and ground gold-cup electrodes (Grass Technologies, Astro-Med Inc., RI, USA) were placed at the temple and forehead respectively. For optimal PhNR recording, a series of red flashes (621 nm, 16 luminous energies between 0.07-12.56 cd.s/m^2, 50 sweeps, 2 Hz flash interval,[41] Figure 1A) on a blue background (470 nm, 10 photopic cd/m^2) was used.

Stimuli were calibrated using the ILT-1700 radiometer (International Light Technologies, MA, USA) with a photopic filter. Participants underwent optical coherence tomography (OCT) to measure retinal nerve fibre layer (RNFL) thickness (Spectralis SD-OCT, Heidelberg Engineering, Dossenheim, Germany).

Study Objectives

The primary objective was to evaluate the change in retinal function as measured by ERG and VF parameters after 12 weeks of high-dose NAM supplementation compared to placebo. Specifically, changes from baseline and placebo in PhNR saturating amplitude (PhNR Vmax), PhNR/b-wave ratio (Vmax ratio) and VF indices (mean deviation, MD; pattern standard deviation, PSD; mean light sensitivity, MLS) were analyzed. Secondary objectives included changes to RNFL thickness, IOP and mean arterial pressure (MAP).

Data analysis

ERG waveforms were processed as described previously (eMethods in Supplement 2).[40] Amplitudes of the b-wave and PhNR (Figure 1B) across the luminance series were modelled using a saturating hyperbolic function,[42,43] defined as $V(I) = Vmax*I^n/(I^n + K^n)$, where V (μV) is the amplitude as a function of luminous exposure (I), Vmax the saturating amplitude (μV), K the semi-saturation constant (1/K is the sensitivity) and n the slope (Figure 1C-D). For the PhNR, n was fixed at 1.2 (consistent with our pilot data, and similar to others).[44,45] Further, the PhNR Vmax was analyzed as a ratio to the b-wave Vmax (Vmax ratio) to account for any changes to the b-wave between sessions.

In addition to VF MD and PSD, the mean light sensitivity (MLS) was calculated as the average of all perimetric sensitivity values on a 24-2 visual field (excluding one point above and below the blind spot). Visual field parameters are conventionally expressed in

logarithmic decibel (dB) scale, however, these were converted to a linear scale (1/lambert) where, $dB = 10 \cdot \log(1/lambert)$ before correlating with other measures.[46,47] The proportion of participants with a ≥ ±1 dB change in MD and PSD in NAM and placebo groups were determined and compared using Fisher's exact test.

Statistical Analysis

Data from one eye per participant were included in the analyses. Prior to study commencement, sample size was calculated based on results of previous work investigating short-term changes in PhNR Vmax ratio following IOP reduction (under review). Assuming an attrition rate of 20%, it was estimated that 48 eyes were required to achieve 80% power to detect a difference between treatment periods with an effect size of 0.56 for Vmax ratio and two-sided hypothesis test with an α level of 0.05.

The primary analysis set included participants who attended all study visits. Statistical analyses were conducted with the statistician masked to intervention using Stata (SE version 15.1, Texas, US). Treatment adherence was compared between randomization groups using the Wilcoxon rank-sum test. As a washout period was not utilized, a pre-test for carryover effects was conducted for each parameter.[48] The within-participant sum of values for each parameter was calculated by adding change from baseline values observed under placebo to those under NAM and compared between randomization groups using two-sample t-test. To test for a period effect, the within participant difference (NAM-PL) was compared between treatment groups using linear regression, adjusting for baseline values of each parameter. The treatment effect for each parameter was assessed following the high-dose period by examining the magnitude and direction of the within-participant difference via linear regression, with adjustment for mean-centred baseline values. Values were analyzed in original units of measurement. If a statistically significant treatment effect was found at 12-weeks for any endpoint, then the 6-week timepoint was also assessed. Changes in PhNR

parameters were also compared to the 95% coefficient of repeatability (COR) established from our previous work.[39]

Missing ERG values were associated with fatigue or persistent muscle twitch during recordings that could not be ameliorated with post-hoc signal processing. Values were multiply imputed (25 imputed datasets) using fully conditional specification (chained equations) with a univariate linear regression imputation model to reduce bias and maintain statistical power. In addition to the imputation variables, imputation models included demographics, clinical data and study group. As a sensitivity analysis, complete-case analyses were performed using the per-protocol set (n = 43) which only included participants who had non-missing data. Results are shown as mean and [95% confidence interval], unless stated otherwise.

Results

Participants

Among 94 participants assessed after medical record screening, 57 were randomized into the study, of which 49 (86%, 65.5±10.0 years, 39% female) completed the study (Figure 2). Majority of participants had primary open angle glaucoma (POAG, 63%), then chronic angle closure glaucoma (16%) and normal tension glaucoma (12%, eFigure 3 in Supplement 2). Adherence rates were high for both NAM and placebo, with >94% adherence to NAM, demonstrating the high tolerability of both low and high-dose NAM supplementation (eTable 1 in Supplement 2). Only two participants (3%) were non-adherent on NAM and removed from analysis after failing to attend all study visits. The participant flow chart is presented in Figure 2 and characteristics of the participants included in the primary analysis in Table 1.

Improvement in Retinal Ganglion Cell Function Following Nicotinamide Treatment

At the 12-week visit, significant improvements in inner retinal function were found in the high-dose NAM arm, with 23% (PhNR Vmax) and 21% (Vmax ratio) of the group improving beyond the respective 95% COR for each measure. Fewer participants on placebo demonstrated improvement (PhNR Vmax: 9%; Vmax ratio: 14%). Some participants deteriorated beyond the COR (9% on placebo, 7% on NAM had a reduced Vmax; 5% on placebo, 2% on NAM had a reduced Vmax ratio). A significant difference in overall treatment effect was found for both Vmax ratio (NAM-PL: 0.01 [0.002, 0.025], $p = 0.02$) and PhNR Vmax (NAM-PL: 1.35 μV [0.159, 2.551], $p = 0.03$, Figure 3A-B, eTable 2 in Supplement 2). PhNR sensitivity (1/K) did not change with treatment (p = 0.41). Overall there was 12.6% [5.0, 20.2] ($p = 0.002$, Figure 3C) improvement in Vmax ratio between baseline and 12-weeks following NAM compared to 3.6% [-3.4, 10.5] ($p = 0.30$) with placebo (between group difference 9.0%, $p = 0.03$). PhNR Vmax improved by 14.8% [2.8, 26.9] ($p = 0.02$, Figure 3D) on NAM, compared to 5.2% [-4.2, 14.6] ($p = 0.27$) on placebo (between group difference 9.6%, $p = 0.04$). There was no evidence of carryover or period effects (eTables 2-3 in Supplement 2) and inference was unchanged in the sensitivity analyses of the complete-case set after omitting participants with missing ERG data (eTable 3 in Supplement 2). In addition, no significant changes were noted at 6-weeks with low-dose NAM or placebo. There was no evidence of a correlation between the PhNR treatment effect and age, sex, or BMI (eFigure 4 in Supplement 2).

In addition, there was no evidence of a treatment effect on ERG measures of outer retinal function including the a-wave (photoreceptoral function, Figure 3E-F) and b-wave (bipolar cell function, Figure 3G-H) amplitudes or implicit times between NAM and placebo. No

differences were found for any b-wave fitting parameters between NAM and placebo groups following the low or high-dose periods (eTable 2 in Supplement 2).

Perimetric Changes with Nicotinamide

There were no significant differences in global VF indices between treatment groups (eTable 2 in Supplement 2). After 12 weeks of NAM, average MD was no different to placebo (NAM-PL: 0.10 dB [-0.33, 0.53], $p = 0.63$, Figure 4A). Similarly, PSD reduced only slightly with NAM (NAM-PL: -0.25 dB [-0.63, 0.14], $p = 0.20$, Figure 4B). Changes in MD and PSD scores for each individual are shown in Figure 4A-B. A greater proportion of participants had an increase in MD by ≥1 dB from baseline following high-dose NAM compared to placebo (27% vs. 16%) and fewer patients taking high-dose NAM had a decrease by ≥1 dB compared to placebo (4% vs 12%, $p = 0.02$, Figure 4C). This was not evident for PSD, where a similar proportion of participants had an increase or decrease by ≥1 dB following NAM and PL ($p = 0.61$, Figure 4D). A moderate positive correlation was found between changes in PhNR Vmax and VF MD at 12 weeks (Figure 4E-F) for both placebo (*Pearson's r* = 0.34, [0.05, 0.57], $p = 0.02$) and NAM treatment (*Pearson's r* = 0.50, [0.24, 0.70], $p = 0.0006$). There was also evidence of a moderate positive correlation between PhNR Vmax and VF MLS (Figure 4G-H) with placebo (*Pearson's r* = 0.37, [0.09, 0.60], $p = 0.01$) and NAM (*Pearson's r* = 0.54, [0.28, 0.72], $p = 0.0002$).

IOP and RNFL Thickness Unchanged

There was no evidence of a difference between placebo and NAM in IOP, MAP or VA (eTable 2 in Supplement 2). IOP was 13.8 ± 4.1 mmHg (mean ± SD) following NAM compared to 13.4 ± 2.4 mmHg following placebo (mean adjusted NAM-PL: 0.2 mmHg [-0.58, 1.003], $p = 0.59$). Overall, there was no change in RNFL thickness. At 12-weeks, the

difference in RNFL thickness compared to baseline was, NAM: -0.3 ± 2.9 μm compared to placebo: 0.4 ± 2.4 μm (mean ± SD, $p = 0.11$).

Adverse effects

In this study, high-dose NAM was well tolerated, the most common side effects being mild gastrointestinal discomfort (constipation or soft stools; 10.5%), nausea (5.3%) and headaches (3.5%). In the placebo group, 12.3% of participants reported difficulty in tablet swallowing, and 7.0% reported gastrointestinal discomfort. One participant withdrew after experiencing tinnitus whilst on placebo treatment. All symptoms resolved after participants ceased treatment.

Discussion

We provide evidence that NAM can lead to an early improvement in inner retinal function in a significant proportion of IOP-treated glaucoma patients after 12-weeks of supplementation. The majority of individuals whose PhNR parameters improved beyond 95% COR also improved in VF MD. Overall, NAM was well tolerated with an adherence rate of >94%. As systemic NAM levels have been shown to be reduced in patients with POAG,[22] NAM supplementation may be a convenient, safe, and cost-effective therapy in conjunction with existing IOP-lowering strategies. A longer-term study is being planned to determine whether these functional improvements are sustained and associated with delayed glaucoma progression.

There is growing evidence that impairments in visual function that occur in experimental and clinical glaucoma may recover following IOP-lowering[7,8,49-53] or in response to the provision of bioenergetic substrates.[9,54] A number of reports have shown short-term improvement in contrast sensitivity and VF parameters in response to IOP-lowering,[8,52,53,55,56] and some

studies indicate that these improvements in visual function are sustained for extended periods.[57,58] Gandolfi et al showed significant improvements in contrast sensitivity 3-9 months after trabeculectomy, which persisted for three years.[8] Caprioli and colleagues also demonstrated improved sensitivity on a point-wise VF analysis with long-term improvement in 44% of VF locations, five years after trabeculectomy.[57] Studies have also provided evidence of ERG improvement following glaucoma treatment. Improvements in pattern electroretinography (PERG) were seen 3-months post-trabeculectomy[49] and following oral acetazolamide.[50] Niyadurupola et al demonstrated increased PhNR amplitude following a >25% IOP reduction.[7] There is less evidence supporting visual recovery by means other than IOP-lowering. Casson and colleagues demonstrated that elevating vitreous glucose levels temporarily improved contrast sensitivity in pseudophakic individuals with POAG, in response to elevations in vitreous glucose levels.[9] In the present study, oral supplementation with the metabolic substrate, NAM, was associated with a 14.8% [2.8%, 26.9%] improvement in PhNR Vmax amplitude and 12.6% [5.0%, 20.2%] improvement in Vmax ratio. Importantly, these effects were independent of IOP. This raises the prospect that oral NAM supplementation may serve as an adjunct to IOP-lowering therapies.

NAD^+ depletion is observed in many tissues with advancing age[59] and serum levels of NAM decline in aged POAG patients.[22] The mechanisms by which NAD^+ may improve RGC function are not known but work in animal models suggest that maintenance of mitochondrial integrity and function is a key factor.[19,23,60-62] High-dose NAM supplementation in DBA/2J glaucoma-model mice prevented RGC soma loss, RNFL thinning, age-related transcriptional and structural changes in mitochondria and preserved RGC function as measured with PERG.[23,60] NAM was protective as a prophylactic and therapeutic intervention in a dose-dependent manner. A similar level of neuroprotection was observed with the overexpression

of NAD^+ biosynthetic enzyme, *Nmnat1* in RGCs.[23] A synergistic effect was found with gene therapy and NAM. Human clinical studies have not previously examined the effect of NAM supplementation on visual function in glaucoma.

NAM is the amide form of vitamin B_3 yet is erroneously referred to as vitamin B_3 in much of the scientific and medical literature. In these contexts, vitamin B_3 encapsulates multiple compounds including niacin/nicotinic acid, which have known ocular and systemic side effects at high doses.[63,64] However, NAM supplements are widely commercially available and are relatively safe. The most common adverse effects reported in prior clinical studies of high-dose NAM (1.5-6 g/day) were skin flushing and nausea (≤1.5%).[25] Longitudinal studies will reveal the tolerability of long-term high-dose NAM supplementation.

We enrolled participants already treated for glaucoma with well-controlled IOP. As IOP was unchanged by oral NAM treatment, the observed effect of NAM on inner retinal function is unlikely to be mediated through changes in IOP. Instead, our findings suggest metabolic rescue of RGCs as a putative mechanism of NAM action. We hypothesise that NAM supplementation may benefit eyes with elevated IOP, which is associated with increased RGC metabolic stress and dysfunction.[2,34] The NAM dosage used in our study was derived empirically from preclinical work and clinical trials of the supplement for other indications. Therefore, it is possible that this dose was sub-optimal and that a single dose is not ideal for all, as pharmacokinetics and pharmacodynamics will differ, for example due to age, sex, or weight.[65,66] However, we did not observe a correlation between treatment effect and baseline demographics. Although a washout period was not utilized, there was no evidence of carryover effects, potentially due to the short plasma half-life of NAM in humans (3.5 hours after a dose of 25 mg/kg).[67]

Conclusions

For the first time, we have provided evidence that oral NAM supplementation leads to an early and measurable improvement in inner retinal function in glaucoma patients already taking IOP-lowering medication. A larger clinical trial of long-term NAM treatment is now warranted to explore whether these effects are sustained and predict a slowing in glaucoma progression.

Tables

Table 1. Baseline characteristics for participants in the primary analysis by treatment group (n = 49).

	Placebo first (n = 23)	**Nicotinamide first** (n = 26)
	n (%)	n (%)
Sex		
Female	10 (43%)	8 (31%)
Male	13 (57%)	18 (69%)
Eye tested		
Left	11 (48%)	16 (62%)
Right	12 (52%)	10 (38%)
Presence of IOL		
No	12 (52%)	14 (54%)
Yes	11 (48%)	12 (46%)
Glaucoma diagnosis		
POAG	14 (61%)	16 (62%)
CACG	5 (22%)	3 (12%)
NTG	2 (9%)	5 (19%)
PXF	1 (4%)	2 (8%)
PDG	1 (4%)	0 (0%)
	Mean (SD)	**Mean (SD)**
Age (years)	67.01 (2.05)	65.30 (2.14)
Visual acuity (logMAR)	0.01 (0.14)	-0.01 (0.11)
Intraocular pressure (mmHg)	13.6 (2.7)	14.5 (3.3)
ERG b-wave fitting parameter: n[a]	1.32 (0.16)	1.29 (0.17)
ERG b-wave Vmax (μV)[a]	108.87 (27.48)	99.00 (29.75)
ERG b-wave fitting parameter: 1/K[a]	1.22 (0.30)	1.12 (0.41)
	Median (Q1, Q3)	**Median (Q1, Q3)**
Mean arterial pressure (mmHg)[a]	92.17 (85.00, 96.00)	95.67 (88.17, 98.67)
ERG PhNR fitting parameter: 1/K[a]	2.40 (1.24, 3.64)	1.64 (1.27, 2.68)
ERG PhNR Vmax (μV)[a]	15.30 (11.10, 20.58)	11.39 (9.31, 13.49)
PhNR Vmax/b-wave Vmax ratio[a]	0.14 (0.11, 0.20)	0.12 (0.10, 0.14)
Visual field MD (24-2) dB	-5.46 (-7.20, -1.10)	-4.51 (-8.37, -1.84)
Visual field PSD (24-2) dB	6.77 (2.37, 9.85)	5.89 (3.06, 9.28)

[a]Missing values in Groups 1 and 2, respectively: ERG b-wave fitting parameter: n, maximum amplitude and fitting parameter: 1/K (n=2 and 3), mean arterial pressure (n=5 and 2), ERG PhNR (μV), fitting parameter: 1/K (n=3 and 3), PhNR Vmax/b-wave Vmax ratio (n=3 and 3). ERG – electroretinogram, IOL – intraocular lens, MD – mean deviation, NTG – normal tension glaucoma, POAG – primary open-angle glaucoma, PDG – pigment dispersion glaucoma, PhNR – photopic negative response, PSD – pattern standard deviation, PXFG – pseudoexfoliative glaucoma, Q1 – lower quartile, Q3 – upper quartile, SD – standard deviation, Vmax – saturated amplitude.

References

1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology.* 2014;121(11):2081-2090.
2. Alqawlaq S, Flanagan JG, Sivak JM. All roads lead to glaucoma: Induced retinal injury cascades contribute to a common neurodegenerative outcome. *Exp Eye Res*. 2019;183:88-97.
3. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. *JAMA.* 2014;311(18):1901-1911.
4. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol.* 2006;90(3):262-267.
5. Wiggs JL, Pasquale LR. Genetics of glaucoma. *Hum Mol Genet.* 2017;26(R1):R21-R27.
6. Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. *Ophthalmology*. 2007;114(2):205-209.
7. Niyadurupola N, Luu CD, Nguyen DQ, et al. Intraocular pressure lowering is associated with an increase in the photopic negative response (PhNR) amplitude in glaucoma and ocular hypertensive eyes. *Invest Ophthalmol Vis Sci.* 2013;54(3):1913-1919.
8. Gandolfi SA, Cimino L, Sangermani C, Ungaro N, Mora P, Tardini MG. Improvement of spatial contrast sensitivity threshold after surgical reduction of intraocular pressure in unilateral high-tension glaucoma. *Invest Ophthalmol Vis Sci.* 2005;46(1):197-201.

9. Casson RJ, Han G, Ebneter A, et al. Glucose-induced temporary visual recovery in primary open-angle glaucoma: a double-blind, randomized study. *Ophthalmology*. 2014;121(6):1203-1211.

10. Fivenson EM, Lautrup S, Sun N, et al. Mitophagy in neurodegeneration and aging. *Neurochem Int*. 2017.

11. Lee S, Sheck L, Crowston JG, et al. Impaired complex-I-linked respiration and ATP synthesis in primary open-angle glaucoma patient lymphoblasts. *Invest Ophthalmol Vis Sci*. 2012;53(4):2431-2437.

12. Osborne NN, del Olmo-Aguado S. Maintenance of retinal ganglion cell mitochondrial functions as a neuroprotective strategy in glaucoma. *Curr Opin Pharmacol*. 2013;13(1):16-22.

13. van de Ven RA, Santos D, Haigis MC. Mitochondrial Sirtuins and Molecular Mechanisms of Aging. *Trends Mol Med*. 2017;23(4):320-331.

14. Mills KF, Yoshida S, Stein LR, et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. *Cell Metab*. 2016;24(6):795-806.

15. Koltai E, Szabo Z, Atalay M, et al. Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats. *Mech Ageing Dev*. 2010;131(1):21-28.

16. Srivastava S. Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders. *Clin Transl Med*. 2016;5(1):25.

17. Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. *Cell Metab*. 2018;27(3):529-547.

18. Liebmann JM, Cioffi GA. Nicking Glaucoma with Nicotinamide? *N Engl J Med*. 2017;376(21):2079-2081.

19. Williams PA, Harder JM, John SWM. Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma. *J Glaucoma.* 2017;26(12):1161-1168.

20. Johnson S, Imai SI. NAD (+) biosynthesis, aging, and disease. *F1000Res.* 2018;7:132.

21. Verdin E. NAD(+) in aging, metabolism, and neurodegeneration. *Science*. 2015;350(6265):1208-1213.

22. Kouassi Nzoughet J, Chao de la Barca JM, Guehlouz K, et al. Nicotinamide Deficiency in Primary Open-Angle Glaucoma. *Invest Ophthalmol Vis Sci*. 2019;60(7):2509-2514.

23. Williams PA, Harder JM, Foxworth NE, et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. *Science.* 2017;355(6326):756-760.

24. Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. *N Engl J Med.* 2015;373(17):1618-1626.

25. Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: a review. *Diabetologia.* 2000;43(11):1337-1345.

26. Viswanathan S, Frishman LJ, Robson JG, Walters JW. The photopic negative response of the flash electroretinogram in primary open angle glaucoma. *Invest Ophthalmol Vis Sci.* 2001;42(2):514-522.

27. Viswanathan S, Frishman LJ, Robson JG, Harwerth RS, Smith EL, 3rd. The photopic negative response of the macaque electroretinogram: reduction by experimental glaucoma. *Invest Ophthalmol Vis Sci.* 1999;40(6):1124-1136.

28. Bui BV, Fortune B. Ganglion cell contributions to the rat full-field electroretinogram. *J Physiol.* 2004;555(Pt 1):153-173.

29. Colotto A, Falsini B, Salgarello T, Iarossi G, Galan ME, Scullica L. Photopic negative response of the human ERG: losses associated with glaucomatous damage. *Invest Ophthalmol Vis Sci.* 2000;41(8):2205-2211.

30. Frishman L, Sustar M, Kremers J, et al. ISCEV extended protocol for the photopic negative response (PhNR) of the full-field electroretinogram. *Doc Ophthalmol.* 2018;136(3):207-211.

31. He Z, Bui BV, Vingrys AJ. Effect of repeated IOP challenge on rat retinal function. *Investigative ophthalmology & visual science.* 2008;49(7):3026-3034.

32. Liu HH, He Z, Nguyen CT, Vingrys AJ, Bui BV. Reversal of functional loss in a rat model of chronic intraocular pressure elevation. *Ophthalmic Physiol Opt.* 2016.

33. Zhao D, Wong VHY, Nguyen CTO, et al. Reversibility of Retinal Ganglion Cell Dysfunction From Chronic IOP Elevation. *Invest Ophthalmol Vis Sci.* 2019;60(12):3878-3886.

34. Crowston JG, Kong YX, Trounce IA, et al. An acute intraocular pressure challenge to assess retinal ganglion cell injury and recovery in the mouse. *Exp Eye Res.* 2015;141:3-8.

35. Fry LE, Fahy E, Chrysostomou V, et al. The coma in glaucoma: Retinal ganglion cell dysfunction and recovery. *Prog Retin Eye Res.* 2018;65:77-92.

36. Kong YX, van Bergen N, Bui BV, et al. Impact of aging and diet restriction on retinal function during and after acute intraocular pressure injury. *Neurobiol Aging.* 2012;33(6):1126 e1115-1125.

37. Chrysostomou V, Galic S, van Wijngaarden P, Trounce IA, Steinberg GR, Crowston JG. Exercise reverses age-related vulnerability of the retina to injury by preventing complement-mediated synapse elimination via a BDNF-dependent pathway. *Aging Cell.* 2016.

38. Crowston JG, Fahy ET, Fry L, et al. Targeting retinal ganglion cell recovery. *Eye (Lond)*. 2017;31(2):196-198.

39. Tang J, Hui F, Hadoux X, et al. A Comparison of the RETeval Sensor Strip and DTL Electrode for Recording the Photopic Negative Response. *Transl Vis Sci Technol.* 2018;7(6):27.

40. Tang J, Hui F, Coote M, Crowston JG, Hadoux X. Baseline Detrending for the Photopic Negative Response. *Transl Vis Sci Technol.* 2018;7(5):9.

41. Hui F, Tang J, Hadoux X, Coote M, Crowston JG. Optimizing a Portable ERG Device for Glaucoma Clinic: The Effect of Interstimulus Frequency on the Photopic Negative Response. *Transl Vis Sci Technol*. 2018;7(6):26.

42. Naka KI, Rushton WA. S-potentials from colour units in the retina of fish (Cyprinidae). *J Physiol*. 1966;185(3):536-555.

43. Fulton AB, Hansen RM. Scotopic stimulus/response relations of the B-wave of the electroretinogram. *Doc Ophthalmol.* 1988;68(3-4):293-304.

44. Binns AM, Mortlock KE, North RV. The relationship between stimulus intensity and response amplitude for the photopic negative response of the flash electroretinogram. *Doc Ophthalmol*. 2011;122(1):39-52.

45. Joshi NR, Ly E, Viswanathan S. Intensity response function of the photopic negative response (PhNR): effect of age and test-retest reliability. *Doc Ophthalmol*. 2017;135(1):1-16.

46. Gardiner SK, Demirel S, Johnson CA, Swanson WH. Assessment of linear-scale indices for perimetry in terms of progression in early glaucoma. *Vision Res*. 2011;51(16):1801-1810.

47. Garway-Heath DF, Holder GE, Fitzke FW, Hitchings RA. Relationship between electrophysiological, psychophysical, and anatomical measurements in glaucoma. *Invest Ophthalmol Vis Sci*. 2002;43(7):2213-2220.

48. Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. *Dtsch Arztebl Int*. 2012;109(15):276-281.

49. Sehi M, Grewal DS, Goodkin ML, Greenfield DS. Reversal of retinal ganglion cell dysfunction after surgical reduction of intraocular pressure. *Ophthalmology*. 2010;117(12):2329-2336.

50. Ventura LM, Porciatti V. Restoration of retinal ganglion cell function in early glaucoma after intraocular pressure reduction: a pilot study. *Ophthalmology*. 2005;112(1):20-27.

51. Salgarello T, Falsini B, Stifano G, et al. Morpho-functional follow-up of the optic nerve in treated ocular hypertension: disc morphometry and steady-state pattern electroretinogram. *Curr Eye Res*. 2008;33(8):709-721.

52. Prata TS, Piassi MV, Melo LA, Jr. Changes in visual function after intraocular pressure reduction using antiglaucoma medications. *Eye (Lond)*. 2009;23(5):1081-1085.

53. Evans DW, Hosking SL, Gherghel D, Bartlett JD. Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection. *Br J Ophthalmol*. 2003;87(12):1463-1465.

54. Shibeeb O, Chidlow G, Han G, Wood JP, Casson RJ. Effect of subconjunctival glucose on retinal ganglion cell survival in experimental retinal ischaemia and contrast sensitivity in human glaucoma. *Clin Exp Ophthalmol*. 2016;44(1):24-32.

55. Gandolfi SA. Improvement of visual field indices after surgical reduction of intraocular pressure. *Ophthalmic Surg.* 1995;26(2):121-126.

56. Wright TM, Goharian I, Gardiner SK, Sehi M, Greenfield DS. Short-term enhancement of visual field sensitivity in glaucomatous eyes following surgical intraocular pressure reduction. *Am J Ophthalmol.* 2015;159(2):378-385 e371.

57. Caprioli J, de Leon JM, Azarbod P, et al. Trabeculectomy Can Improve Long-Term Visual Function in Glaucoma. *Ophthalmology.* 2016;123(1):117-128.

58. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Glaucoma Laser Trial Research Group. *Am J Ophthalmol.* 1995;120(6):718-731.

59. Katsyuba E, Auwerx J. Modulating NAD+ metabolism, from bench to bedside. *EMBO J.* 2017.

60. Williams PA, Harder JM, Cardozo BH, Foxworth NE, John SWM. Nicotinamide treatment robustly protects from inherited mouse glaucoma. *Commun Integr Biol.* 2018;11(1):e1356956.

61. Gueven N, Nadikudi M, Daniel A, Chhetri J. Targeting mitochondrial function to treat optic neuropathy. *Mitochondrion.* 2016.

62. Kamel K, Farrell M, O'Brien C. Mitochondrial dysfunction in ocular disease: Focus on glaucoma. *Mitochondrion.* 2017;35:44-53.

63. Domanico D, Verboschi F, Altimari S, Zompatori L, Vingolo EM. Ocular Effects of Niacin: A Review of the Literature. *Med Hypothesis Discov Innov Ophthalmol.* 2015;4(2):64-71.

64. Ranchoff RE, Tomecki KJ. Niacin or niacinamide? Nicotinic acid or nicotinamide? What is the difference? *J Am Acad Dermatol.* 1986;15(1):116-117.

65. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. *Clinical pharmacology and therapeutics*. 2007;82(1):87-96.

66. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. *Clin Pharmacokinet.* 2009;48(3):143-157.

67. Petley A, Macklin B, Renwick AG, Wilkin TJ. The pharmacokinetics of nicotinamide in humans and rodents. *Diabetes.* 1995;44(2):152-155.


A
luminous energy
cd.s/m2
20 µV
12.6
6.3
3.2
1.6
0.8
0.4
0.2
0.1
0
50
100
150
time (ms)
B
20 µV
50 ms
PhNR
a-wave
b-wave
C
b-wave
amplitude (µV)
80
60
40
20
0
ERG
model
0.1
1
10
D
PhNR
Vmax
n
K
amplitude (µV)
15
10
5
0
0.1
1
10
luminous energy (cd.s/m2)


n = 94
Assessed for study eligibility after initial screening of medical records
Excluded (n = 37)
n = 9, did not meet inclusion criteria
n = 28, declined to participate
n = 57
Randomized
Baseline measurement
n = 27
Treatment group 1: Placebo first
Received placebo (n = 26)
Discontinued intervention after randomization (n = 1, AE)
n = 30
Treatment group 2: Nicotinamide first
Received nicotinamide (n = 27)
Lost to follow-up after randomization (n = 2)
Discontinued intervention after 6-week visit (n = 1, SE)
n = 26
Nicotinamide second
Received nicotinamide (n = 23)
Discontinued intervention after 6-week visit (n = 2)
Lost to follow-up after 6-week visit (n = 1)
n = 27
Placebo second
Received placebo (n = 26)
Lost to follow-up after 6-week visit (n = 1)
Total analyzed, n = 49
Primary analysis, n = 49
Per-protocol, n = 43


A
Vmax ratio
treatment - control
0.04
0.02
0.00
-0.02
-0.04
*
NAM6 - PL6
NAM12 - PL12
B
PhNR Vmax
treatment - control (µV)
4
2
0
-2
-4
*
NAM6 - PL6
NAM12 - PL12
inner retina
C
Vmax ratio
relative change from baseline (%)
40
20
0
-20
**
PL6
PL12
NAM6
NAM12
D
PhNR Vmax
relative change from baseline (%)
40
20
0
-20
*
PL6
PL12
NAM6
NAM12
treatment group
E
a-wave
amplitude (µV)
50
40
30
20
10
0
-10
F
a-time
time (ms)
30
25
20
15
10
Base
PL6
PL12
NAM6
NAM12
photoreceptor
G
b-wave
amplitude (µV)
140
120
100
80
60
40
20
0
0.07
0.14
0.30
0.60
1.10
2.20
4.50
8.90
H
b-time
time (ms)
50
40
30
20
10
0.07
0.14
0.30
0.60
1.10
2.20
4.50
8.90
bipolar cell
luminous energy (cd.s/m2)


A
difference in MD (dB)
6
3
0
-3
-6
NAM6 - PL6
NAM12 - PL12
B
difference in PSD (dB)
8
4
0
-4
-8
NAM6 - PL6
NAM12 - PL12
C
VF MD
*
% of participants
30
20
10
0
PL12 - base
NAM12 - base
D
VF PSD
> -1 dB
> +1 dB
% of participants
30
20
10
0
PL12 - base
NAM12 - base
E
-6 dB
-3 dB
0 dB
PhNR Vmax (µV)
30
20
10
0
0.0
0.5
1.0
VF MD (1/lambert)
F
-6 dB
-3 dB
0 dB
PhNR Vmax (µV)
30
20
10
0
0.0
0.5
1.0
VF MD (1/lambert)
G
PhNR Vmax (µV)
30
20
10
0
0
500
1000
1500
VF MLS (1/lambert)
H
PhNR Vmax (µV)
30
20
10
0
0
500
1000
1500
VF MLS (1/lambert)